Keywords: Arena Pharma, Eisai, Lorcaserin, Obesity, CRL response
Arena and Eisai release data on obesity drug candidate lorcaserin to be used in CRL response
Article | 03 August 2011
USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese partner Eisai (TYO: 4523) announced the completion of a clinical study that measured lorcaserin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
